New hope for Tough-to-Treat stomach tumors after first drug fails
NCT ID NCT06087263
Summary
This study is testing if the drug regorafenib can help control the growth of advanced gastrointestinal stromal tumors (GIST) in patients whose cancer has specific genetic mutations and worsened after their first treatment. It is for adults whose cancer has spread or cannot be removed by surgery and who have already tried and stopped the drug imatinib. The main goal is to see if regorafenib can delay the cancer from getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL STROMAL TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.